

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | | |
|---|-----------|--------------|--|--|--|---|--|--|
| 1. Name and Address of Reporting Person* <u>Secora Michael</u> | | | 2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS, INC. [RXXR]</u> | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ Chief Financial Officer | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) <u>11/14/2023</u> | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person | | |
| C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | |
| (Street) | | | Rule 10b5-1(c) Transaction Indication | | | | | |
| <u>SALT LAKE CITY</u> | <u>UT</u> | <u>84101</u> | <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Class A Common Stock | 11/14/2023 | | M ⁽¹⁾ | | 37,500 | A | \$2.22 | 950,686 | D | |
| Class A Common Stock | 11/14/2023 | | S ⁽¹⁾ | | 25,000 | D | \$6.3177 ⁽²⁾ | 925,686 | D | |
| Class A Common Stock | 11/15/2023 | | M ⁽¹⁾ | | 37,500 | A | \$2.22 | 963,186 | D | |
| Class A Common Stock | 11/15/2023 | | S ⁽¹⁾ | | 20,300 | D | \$7.2506 ⁽³⁾ | 942,886 | D | |
| Class A Common Stock | 11/15/2023 | | S ⁽¹⁾ | | 4,700 | D | \$7.6168 ⁽⁴⁾ | 938,186 | D | |
| Class A Common Stock | 11/15/2023 | | F ⁽⁵⁾ | | 7,172 | D | \$7.18 | 931,014 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$2.22 | | | | | | (6) | 03/03/2030 | Class A Common Stock | 0 | 685,177 | D | | |
| Stock Option (Right to Buy) | \$2.22 | 11/14/2023 | | M ⁽¹⁾ | | 37,500 | (7) | 03/03/2030 | Class A Common Stock | 37,500 | \$0.00 | 1,222,635 | D | |
| Stock Option (Right to Buy) | \$2.22 | 11/15/2023 | | M ⁽¹⁾ | | 37,500 | (7) | 03/03/2030 | Class A Common Stock | 37,500 | \$0.00 | 1,185,135 | D | |
| Stock Option (Right to Buy) | \$11.14 | | | | | | (8) | 02/04/2032 | Class A Common Stock | 0 | 116,684 | D | | |
| Stock Option (Right to Buy) | \$11.14 | | | | | | | 02/04/2022 | 02/04/2032 | Class A Common Stock | 0 | 3,914 | D | |
| Stock Option (Right to Buy) | \$8.55 | | | | | | (9) | 02/01/2033 | Class A Common Stock | 0 | 404,857 | D | | |

Explanation of Responses:

- Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.
- This transaction was executed in multiple trades at prices ranging from \$6.13 to \$6.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from \$6.51 to \$7.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from \$7.51 to \$7.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
6. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
7. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
9. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

/s/ Jonathan Golightly,
attorney-in-fact

11/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.